Stock itci.

Stock analysis for Intra-Cellular Therapies Inc (ITCI:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Intra-Cellular Therapies (ITCI) shares soared 16.4% in the last trading session to close at $55.73. The move was backed by solid volume with far more shares changing hands than in a normal session.If you’re just getting started, tracking investments might seem like a mystery. Thankfully, modern tools and technology make it easier than ever to figure out how to manage your stock portfolio and to track it. This quick guide gives you ti...Intra-Cellular (ITCI) Q2 Earnings & Sales Top, '23 View Raised. 08/04/23-7:40AM EST Zacks. Price is a widely used stock evaluation measure. Find the latest Price for IntraCellular Therapies (ITCI)

Intra-Cellular Therapies (ITCI) Jefferies analyst Andrew Tsai maintained a Buy rating on Intra-Cellular Therapies on October 6 and set a price target of $95.00 . The company’s shares closed last ...

000156751412-312023Q3false13600015675142023-01-012023-09-3000015675142023-10-31xbrli:shares00015675142023-09 …

Stock Target Advisor’s own stock analysis of Intracellular Th is Slightly Bearish, which is based on 3 positive signals and 5 negative signals. At the last closing, Intracellular Th’s stock price was USD 53.66. Intracellular Th’s stock price has changed by +5.28% over the past week, -6.30% over the past month and +14.24% over the last year.Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you.Intra-Cellular Therapies ( NASDAQ: ITCI) stock traded much higher recently after it had obtained FDA approval for its drug CAPLYTA (lumateperone) for the treatment of adults with bipolar ...Get Intra-Cellular Therapies Inc (ITCI.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investmentsIntra-Cellular (ITCI) delivered earnings and revenue surprises of 26.98% and 3.44%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Ticker Symbol: ITCI: Exchange: NASDAQ: Fiscal Year: January - December: Reporting Currency: USD: CIK Code: 0001567514: CUSIP Number: 46116X101: ISIN Number: US46116X1019

TimesSquare Capital highlighted stocks like Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) in its Q3 2022 investor letter. Headquartered in New York, New York, Intra-Cellular Therapies, Inc. (NASDAQ ...

CAPLYTA is a prescription medication used in adults for the treatment of depressive episodes associated with bipolar I or bipolar II disorder (bipolar depression). CAPLYTA can be taken alone or with the medicines lithium or valproate for bipolar depression. It is not known if CAPLYTA is safe and effective in children.Have the markets turned the corner? Maybe not – but maybe so, at least for the short term. Despite rising inflation in the States, and Russia’s continuing war against Ukraine, high prices for ...Complete Intra-Cellular Therapies Inc. stock information by Barron's. View real-time ITCI stock price and news, along with industry-best analysis.A. The latest price target for Intra-Cellular Therapies ( NASDAQ: ITCI) was reported by RBC Capital on Friday, November 3, 2023. The analyst firm set a price target for 76.00 expecting ITCI to ...ITCI 4.98%. 58. See ITCI Report. Overall market sentiment has been high on Intra-Cellular Therapies Inc ( ITCI) stock lately. ITCI receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator. Intra-Cellular Therapies Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ITCI!

TimesSquare Capital highlighted stocks like Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) in its Q3 2022 investor letter. Headquartered in New York, New York, Intra-Cellular Therapies, Inc ...Shares of ITCI responded in kind, rallying 16% in the subsequent trading session and ultimately 40% higher to an all-time high of $67.05 in June 2023, suggesting peak sales of $1.75 billion to $2. ...Have the markets turned the corner? Maybe not – but maybe so, at least for the short term. Despite rising inflation in the States, and Russia’s continuing war against Ukraine, high prices for ...ITCI The Nasdaq Global ... On January 10, 2020, the Company completed a public offering of common stock in which the Company sold ...With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.Intra-Cellular Therapeutics (ITCI) announces positive top-line data from its phase III study evaluating lumateperone for the treatment of depression. Stock surges 16% following the news.

The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $78.67. ITCI has been the topic of a number of research analyst reports. Needham & Company LLC lifted their target price on Intra-Cellular Therapies from $71.00 to $72.00 and gave the stock a “buy” rating in a report on Friday ...

Shares of ITCI responded in kind, rallying 16% in the subsequent trading session and ultimately 40% higher to an all-time high of $67.05 in June 2023, suggesting peak sales of $1.75 billion to $2. ...Notably, institutional investors and hedge funds currently own approximately 85.70% of ITCI stock. This demonstrates their trust in Intra-Cellular Therapies’ ability to revolutionize treatment options for neuropsychiatric and neurological disorders. On Friday, ITCI shares opened at $62.27. The firm has maintained a 50-day moving average price ...Have the markets turned the corner? Maybe not – but maybe so, at least for the short term. Despite rising inflation in the States, and Russia’s continuing war against Ukraine, high prices for ...The mean of analysts' price targets for Intra-Cellular (ITCI) points to a 33% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong …ITCI Earnings Date and Information. Intra-Cellular Therapies last released its quarterly earnings results on November 2nd, 2023. The biopharmaceutical company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.34. The business earned $126.17 million during the quarter, compared to the consensus estimate of ...According to 8 analysts, the average rating for ITCI stock is "Strong Buy." The 12-month stock price forecast is $78.5, which is an increase of 24.92% from the latest price. Price TargetSince its IPO on the Shenzhen stock exchange, its share price has gone up every day by the exact same amount. Baofeng Technologies is China’s best performing stock this year. Since its IPO on the Shenzhen stock exchange, its share price has...Get Intra-Cellular Therapies Inc (ITCI.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investmentsAs of April 23, 2023, the average one-year price target for Intra-Cellular Therapies is 77.93. The forecasts range from a low of 56.56 to a high of $102.90. The average price target represents an ...

Intra-Cellular Therapies ( NASDAQ: ITCI) stock traded much higher recently after it had obtained FDA approval for its drug CAPLYTA (lumateperone) for the treatment of adults with bipolar ...

NEW YORK, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Thursday, …

Nov 27, 2023 · A high-level overview of Intra-Cellular Therapies, Inc. (ITCI) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Nov 7, 2023 · The mean of analysts' price targets for Intra-Cellular (ITCI) points to a 41.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement ... Investing in the stock market takes a lot of courage, a lot of research, and a lot of wisdom. One of the most important steps is understanding how a stock has performed in the past. Of course, the past is not a guarantee of future performan...Nov 30, 2023 · IntraCellular Therapies - ITCI - Stock Price Today - Zacks IntraCellular Therapies (ITCI) (Delayed Data from NSDQ) $61.37 USD +1.94 (3.26%) Updated Nov 30, 2023 04:00 PM ET After-Market:... home / stock / itci / itci news. RSS . ITCI ITCI Quote ITCI Short ITCI News ITCI Articles ITCI Message Board. March, 09 2021 08:51 AM | Financial News Media | More on ITCI. ITCI; ITCI Quote; ... (NASDAQ:ITCI), and Pfizer Inc. (NYSE:PFE) are helping to make this change happen. Numinus Wellness Shares Promising Developments .Nov 23, 2022 · Shares of Intra-Cellular Therapies (ITCI) have gained 18.4% over the past four weeks to close the last trading session at $52.87, but there could still be a solid upside left in the stock if short ... Intra-Cellular Therapies ( NASDAQ: ITCI) stock traded much higher recently after it had obtained FDA approval for its drug CAPLYTA (lumateperone) for the treatment of adults with bipolar ...Get up to 10 years of daily historical stock prices & volumes. The "Close/Last" is the “adjust consolidated close price”. Data provided by Edgar Online. The net and percent change in the quote ...Press Releases. Year. November 15, 2023. Intra-Cellular Therapies to Present at the 6th Annual Evercore ISI HealthCONx Conference. PDF Version. November 2, 2023. Intra-Cellular Therapies Reports Third Quarter 2023 Financial Results and Raises 2023 CAPLYTA Sales Guidance. PDF Version. October 31, 2023.Intra-Cellular Therapies, Inc. (ITCI) NasdaqGS - NasdaqGS Real Time Price. Currency in USD. Follow. 2W 10W 9M. 62.84 +1.47 (+2.40%) At close: 04:00PM EST. 60.44 -2.40 (-3.82%) After hours:...

Nov 7, 2023 · by Zacks Equity Research Published on November 07,2023. The mean of analysts' price targets for Intra-Cellular (ITCI) points to a 41.2% upside in the stock. While this highly sought-after metric ... Disruption hit MTR services to Hong Kong’s airport for about an hour on Sunday, because of a fault with the baggage handling system at Airport station. Services were back to normal by 1.25pm. The total journey time on the Airport Express from Hong Kong station to AsiaWorld-Expo station was extended by five to 10 minutes, according to …Aug 12, 2023 · According to Seeking Alpha data: ITCI capital structure reveals a market cap of $5.59B with minimal debt and a healthy cash reserve, resulting in an enterprise value of $5.10B. Instagram:https://instagram. first alliedaugmented reality stockmacys nike shoescolumbus energy Nov 24, 2023 · So, when comparing one stock to another in a different industry, it's best make relative comparisons to that stock's respective industry values. -36.92% -224.88% va home loans floridacan you day trade on fidelity Intra-Cellular Therapies Inc. stock grades by Barron's. View ITCI fundamental and sentiment analysis powered by MarketGrader.Nowadays finding high-quality stock photos for personal or commercial use is very simple. You just need to search the photo using a few descriptive words and let Google do the rest of the work. buy databricks stock ETFs with Intra-Cellular Therapies, Inc. (ITCI). 68. ETFs Hold ITCI. 8.2M. ITCI Shares in ETFs. IWM. Biggest Holder. PSIL. Largest Allocation ...Christopher Alafi ITCI stock SEC Form 4 insiders trading. Christopher has made over 21 trades of the Intra-Cellular Therapies Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 47,325 units of ITCI stock worth $1,897,733 on 27 May 2021.. The largest trade he's ever made was buying 625,000 units …The latest Intra-Cellular Therapies stock prices, stock quotes, news, and ITCI history to help you invest and trade smarter.